Giuseppe Derosa^{1, 2,}, Angela D’Angelo^{3, 4}, Giovanni V. Gaudio⁵, Luigina Guasti⁶

Non-alcoholic fatty liver disease (NAFLD) represents the leading cause of liver disease and is characterized by obesity, hyperglycemia, insulin-resistance, dyslipidemia and hypertension. The aim of this study was to evaluate if Olife® consumption in patients with NAFLD could improve fatty liver grade and related metabolic and inflammatory parameters. Eighty-two Caucasian patients aged ≥ 18 of both sexes diagnosed with NAFLD, according to practice guidelines, were enrolled in a single-center, double-blind, open label, randomized, controlled study. Patients were randomized to follow a standardized Diet or a standardized Diet + Olife® for 3 months. No changes in BMI, circumference, FPG, TC, LDL-C, HDL-C and Tg were observed with either treatment. In the group of patients receiving Diet + Olife®, a significant decrease in hs-CRP and TNF-α as well as an increase in ADN (p < 0.05 compared to Baseline and Diet) was observed, respectively. Transaminases and γ-GT were significantly reduced (p < 0.05 vs Baseline and Diet) in Diet + Olife® group compared to Diet group, respectively. In addition, AST/ALT ratio and HIS were significantly lower (p < 0.05 vs Baseline and Diet) in the Diet + Olife® group compared to Diet group, respectively. All patients showed signs of hepatic steatosis improvement or disappearance. In conclusion Olife® added to Diet ameliorates hepatic parameters and echography grading, and manages to reduce inflammatory parameters during the 3 months of study.

food supplement, oleuropein, elenolic acid, rutin, hydroxytyrosol, tyrosol, hepatic steatosis